Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease / Krentz, Andrew J. ; Weyer, Christian ; Hompesch, Marcus  

Público ISBD Ningún comentario para este título. Título : Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease : A Focus on Early Phase Clinical Drug Development Tipo de documento: documento electrónico Autores: Krentz, Andrew J., ; Weyer, Christian, ; Hompesch, Marcus, Mención de edición: 2 ed. Editorial: [s.l.] : Springer Fecha de publicación: 2019 Número de páginas: XI, 556 p. 115 ilustraciones, 59 ilustraciones en color. ISBN/ISSN/DL: 978-3-030-11748-1 Nota general: Libro disponible en la plataforma SpringerLink. Descarga y lectura en formatos PDF, HTML y ePub. Descarga completa o por capítulos. Idioma : Inglés (eng) Palabras clave: Enfermedades  Farmacología Clasificación: 616 Medicina interna Resumen: Este libro tiene como objetivo ayudar a la selección de los métodos más apropiados para su uso en estudios clínicos de fase temprana (1 y 2) de nuevos medicamentos para la diabetes, la obesidad, la enfermedad del hígado graso no alcohólico (NAFLD) y los trastornos cardiometabólicos relacionados. Los métodos de investigación clínica para evaluar la farmacocinética y la farmacodinamia de los nuevos medicamentos para la diabetes, por ejemplo, la técnica de pinza euglucémica, se han consolidado en los estudios de prueba de mecanismo. Sin embargo, la selección de las técnicas más apropiadas no es en absoluto sencilla. Además, la aplicación de dichos métodos debe cumplir los requisitos reglamentarios para los nuevos medicamentos. Este libro analiza la necesidad de nuevas farmacoterapias para la diabetes, la obesidad y la NAFLD y los objetivos moleculares de los medicamentos actualmente en desarrollo. Se consideran las tecnologías emergentes, como la imagen funcional, los biomarcadores circulantes y los ómicos, junto con cuestiones prácticas y éticas relacionadas con los ensayos clínicos de fase temprana en sujetos con trastornos cardiometabólicos. Los métodos de investigación traslacional en diabetes, obesidad y enfermedad del hígado graso no alcohólico son de interés para científicos biomédicos, farmacólogos, académicos involucrados en la investigación metabólica y médicos que practican estas especialidades. Nota de contenido: Part 1: Review of Clinical Investigative Methods -- Chapter 1: Quantifying Insulin Action in Humans -- Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function -- Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins -- Chapter 4: Measurement of Energy Expenditure -- Chapter 5: QUANTIFYING APPETITE AND SATIETY -- Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition -- Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development -- Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes -- Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates -- Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders -- Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH -- Chapter 12: Omics: Potential role in early phase drug development -- Part 2: Preclinical Drug Development and Transitioning to Clinical Studies -- Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases -- Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS – CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT -- Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c -- Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis -- Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview -- Chapter 18: Transitioning from Preclinical to Clinical Drug Development -- Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders -- Chapter 20: Early Phase Metabolic Research with Reference to Special Populations. Tipo de medio : Computadora Summary : This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties. Enlace de acceso : https://link-springer-com.biblioproxy.umanizales.edu.co/referencework/10.1007/97 [...] Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease : A Focus on Early Phase Clinical Drug Development [documento electrónico] / Krentz, Andrew J., ; Weyer, Christian, ; Hompesch, Marcus,  . -  2 ed.  . - [s.l.] : Springer, 2019 . - XI, 556 p. 115 ilustraciones, 59 ilustraciones en color. ISBN : 978-3-030-11748-1 Libro disponible en la plataforma SpringerLink. Descarga y lectura en formatos PDF, HTML y ePub. Descarga completa o por capítulos. Idioma : Inglés (eng) Palabras clave: Enfermedades  Farmacología Clasificación: 616 Medicina interna Resumen: Este libro tiene como objetivo ayudar a la selección de los métodos más apropiados para su uso en estudios clínicos de fase temprana (1 y 2) de nuevos medicamentos para la diabetes, la obesidad, la enfermedad del hígado graso no alcohólico (NAFLD) y los trastornos cardiometabólicos relacionados. Los métodos de investigación clínica para evaluar la farmacocinética y la farmacodinamia de los nuevos medicamentos para la diabetes, por ejemplo, la técnica de pinza euglucémica, se han consolidado en los estudios de prueba de mecanismo. Sin embargo, la selección de las técnicas más apropiadas no es en absoluto sencilla. Además, la aplicación de dichos métodos debe cumplir los requisitos reglamentarios para los nuevos medicamentos. Este libro analiza la necesidad de nuevas farmacoterapias para la diabetes, la obesidad y la NAFLD y los objetivos moleculares de los medicamentos actualmente en desarrollo. Se consideran las tecnologías emergentes, como la imagen funcional, los biomarcadores circulantes y los ómicos, junto con cuestiones prácticas y éticas relacionadas con los ensayos clínicos de fase temprana en sujetos con trastornos cardiometabólicos. Los métodos de investigación traslacional en diabetes, obesidad y enfermedad del hígado graso no alcohólico son de interés para científicos biomédicos, farmacólogos, académicos involucrados en la investigación metabólica y médicos que practican estas especialidades. Nota de contenido: Part 1: Review of Clinical Investigative Methods -- Chapter 1: Quantifying Insulin Action in Humans -- Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function -- Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins -- Chapter 4: Measurement of Energy Expenditure -- Chapter 5: QUANTIFYING APPETITE AND SATIETY -- Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition -- Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development -- Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes -- Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates -- Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders -- Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH -- Chapter 12: Omics: Potential role in early phase drug development -- Part 2: Preclinical Drug Development and Transitioning to Clinical Studies -- Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases -- Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS – CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT -- Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c -- Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis -- Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview -- Chapter 18: Transitioning from Preclinical to Clinical Drug Development -- Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders -- Chapter 20: Early Phase Metabolic Research with Reference to Special Populations. Tipo de medio : Computadora Summary : This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties. Enlace de acceso : https://link-springer-com.biblioproxy.umanizales.edu.co/referencework/10.1007/97 [...]

---

1 (1 - 1 / 1) Ver por página : 25 50 100 200